Methylprednisolone versus intravenous immune globulin as an initial therapy in adult primary immune thrombocytopenia
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Few studies have addressed whether there are differences in clinical efficacy between intravenous methylprednisolone (methyl-Pd) and intravenous immunoglobulin (IVIg) use. Methods: We retrospectively compared platelet responses and toxicities associated with these two treatments in adult patients with immune thrombocytopenia. Patients received intravenous methyl-Pd therapy followed by oral prednisolone (Pd) from 1993 to 2002 and IVIg together with oral Pd from 2003 to 2008. Results: Early response and maintenance of the response were assessed at 7 days and 6 months after treatment, respectively. Of the 87 patients enrolled, 77 (88.5%) were eligible for analysis. Early responses occurred in 30 of 39 patients (76.9%) receiving methyl-Pd versus 33 of 38 patients (86.6%) receiving IVIg (p = 0.187). The response was maintained in 28 patients (71.8%) in the methyl-Pd arm and in 23 patients (60.5%) in the IVIg arm (p = 0.187). The time to a complete response in the IVIg arm (6 days; range, 1 to 35) was shorter than that in the methyl-Pd arm (13.5 days; range, 2 to 29) (p = 0.002). Side effects were mild and tolerable in both arms. Five years after initiating treatment, 7 of 18 patients (38.9%) and five of 14 patients (35.7%) were still maintaining a response in the methyl-Pd and IVIg arms, respectively. Conclusions: These results indicate that neither the early response rate nor the long-term outcome differed between the methyl-Pd and IVIg treatments. However, IVIg induced a complete response more rapidly than did methyl-Pd.
Abstract
Background/Aims: Few studies have addressed whether there are differences in clinical efficacy between intravenous methylprednisolone (methyl-Pd) and intravenous immunoglobulin (IVIg) use. Methods: We retrospectively compared platelet responses and toxicities associated with these two treatments in adult patients with immune thrombocytopenia. Patients received intravenous methyl-Pd therapy followed by oral prednisolone (Pd) from 1993 to 2002 and IVIg together with oral Pd from 2003 to 2008. Results: Early response and maintenance of the response were assessed at 7 days and 6 months after treatment, respectively. Of the 87 patients enrolled, 77 (88.5%) were eligible for analysis. Early responses occurred in 30 of 39 patients (76.9%) receiving methyl-Pd versus 33 of 38 patients (86.6%) receiving IVIg (p = 0.187). The response was maintained in 28 patients (71.8%) in the methyl-Pd arm and in 23 patients (60.5%) in the IVIg arm (p = 0.187). The time to a complete response in the IVIg arm (6 days; range, 1 to 35) was shorter than that in the methyl-Pd arm (13.5 days; range, 2 to 29) (p = 0.002). Side effects were mild and tolerable in both arms. Five years after initiating treatment, 7 of 18 patients (38.9%) and five of 14 patients (35.7%) were still maintaining a response in the methyl-Pd and IVIg arms, respectively. Conclusions: These results indicate that neither the early response rate nor the long-term outcome differed between the methyl-Pd and IVIg treatments. However, IVIg induced a complete response more rapidly than did methyl-Pd.
참고문헌 (15)
- Rodeghiero F, "Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children : report from an international working group", Blood, 113, pp.2386~2393 (2009)
- Neunert C, "The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia", Blood, 117, pp.4190~4207 (2011)
- Provan D, "International consensus report on the investigation and management of primary immune thrombocytopenia", Blood, 115, pp.168~186 (2010)
- Godeau B, "Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura : a randomised, multicentre trial", Lancet, 359, pp.23~29 (2002)
- Cheng Y, "Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone", N Engl J Med, 349, pp.831~836 (2003)
- Mazzucconi MG, "Therapy with high-dose dexamethasone(HD-DXM)in previously untreated patients affected by idiopathic thrombocytopenic purpura : a GIMEMA experience", Blood, 109, pp.1401~1407 (2007)
- Zaja F, "Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia", Blood, 115, pp.2755~2762 (2010)
- Gudbrandsdottir S, "Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia", Blood, 121, pp.1976~1981 (2013)
- Newland AC, "High-dose intravenous IgG in adults with autoimmune thrombocytopenia", Lancet, 1, pp.84~87 (1983)
- Gelfand EW, "Intravenous immune globulin in autoimmune and inflammatory diseases", N Engl J Med, 367, pp.2015~2025 (2012)
- Siragam V, "Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells", Nat Med, 12, pp.688~692 (2006)
- Schoonen WM, "Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database", Br J Haematol, 145, pp.235~244 (2009)
- Norgaard M, "Long-term clinical outcomes of patients with primary chronic immune thrombocytopenia : a Danish population-based cohort study", Blood, 117, pp.3514~3520 (2011)
- Cines DB, "How I treat idiopathic thrombocytopenic purpura(ITP)", Blood, 106, pp.2244~2251 (2005)
- Andres E, "Gender-related analysis of the clinical presentation, treatment response and outcome in patients with immune thrombocytopenia", Presse Med, 41, pp.e426~e431 (2012)